select a format

Single User License
USD 2000 INR 0
Site License
USD 4000 INR 0
Corporate User License
USD 6000 INR 0


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Acinetobacter Infections-Pipeline Review, H1 2015

Acinetobacter Infections-Pipeline Review, H1 2015

  • Products Id :- GMDHC6587IDB
  • |
  • Pages: 114
  • |
  • May 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Acinetobacter Infections-Pipeline Review, H1 2015


Global Markets Direct's, 'Acinetobacter Infections-Pipeline Review, H1 2015', provides an overview of the Acinetobacter Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acinetobacter Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acinetobacter Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acinetobacter Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Acinetobacter Infections Overview 11

Therapeutics Development 12

Pipeline Products for Acinetobacter Infections-Overview 12

Pipeline Products for Acinetobacter Infections-Comparative Analysis 13

Acinetobacter Infections-Therapeutics under Development by Companies 14

Acinetobacter Infections-Therapeutics under Investigation by Universities/Institutes 16

Acinetobacter Infections-Pipeline Products Glance 17

Clinical Stage Products 17

Early Stage Products 18

Acinetobacter Infections-Products under Development by Companies 19

Acinetobacter Infections-Products under Investigation by Universities/Institutes 22

Acinetobacter Infections-Companies Involved in Therapeutics Development 23

Achaogen Inc. 23

Adenium Biotech ApS 24

AmpliPhi Biosciences Corporation 25

Aridis Pharmaceuticals LLC 26

AstraZeneca PLC 27

AvidBiotics Corp. 28

ConjuGon, Inc. 29

Emergent BioSolutions Inc. 30

FAB Pharma 31

LegoChem Biosciences, Inc 32

Melinta Therapeutics, Inc 33

Microbiotix, Inc. 34

Northern Antibiotics Oy 35

Nosopharm SAS 36

Novan, Inc. 37

Omnia Molecular Ltd. 38

Pfizer Inc. 39

Phylogica Limited 40

Sarepta Therapeutics, Inc. 41

Sealife PHARMA GMBH 42

Shionogi & Co., Ltd. 43

Synthetic Biologics, Inc. 44

Techulon, Inc. 45

Trana Discovery, Inc. 46

Vaxdyn, S.L. 47

Acinetobacter Infections-Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Combination Products 49

Assessment by Target 50

Assessment by Mechanism of Action 52

Assessment by Route of Administration 54

Assessment by Molecule Type 56

Drug Profiles 58

A-3APO-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AA-139-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ACHN-975 Prodrug-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Antisense Oligonucleotide for Acinetobacter baumannii Infections-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Antisense Oligonucleotide for Acinetobacter Baumannii Infections-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

AR-401-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Biologics for Acinetobacter Baumanii-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

BXN-112-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Cephalosporin + Beta-Lactamase Inhibitor-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

EV-035-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Fab-001-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

GN-4474-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

LCB-100200-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

MBX-1162-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

MDN-0057-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

MDN-0058-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

MDN-0059-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

MDN-0060-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Monoclonal Antibodies for Gram-Negative Bacterial Infections-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

NAB-7061-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

NAB-739-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

NAB-741-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

NOSO-95300-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

NVN-1000-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

NVN-4428-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

RX-05-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

RXP-873-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

S-649266-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

SLP-0905-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Small Molecule for Acinetobacter baumannii Infections-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Small Molecule for Gram-Negative Nosocomial Infections-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Small Molecules for Gram-Negative Bacterial Infections-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Small Molecules for Multi-Drug Resistant Bacterial Infections-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

SYN-001-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

VXD-001-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

VXD-003-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

Acinetobacter Infections-Recent Pipeline Updates 108

Acinetobacter Infections-Dormant Projects 112

Appendix 113

Methodology 113

Coverage 113

Secondary Research 113

Primary Research 113

Expert Panel Validation 113

Contact Us 113

Disclaimer 114

List of Tables

Number of Products under Development for Acinetobacter Infections, H1 2015 12

Number of Products under Development for Acinetobacter Infections-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Development by Companies, H1 2015 (Contd..2) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Acinetobacter Infections-Pipeline by Achaogen Inc., H1 2015 23

Acinetobacter Infections-Pipeline by Adenium Biotech ApS, H1 2015 24

Acinetobacter Infections-Pipeline by AmpliPhi Biosciences Corporation, H1 2015 25

Acinetobacter Infections-Pipeline by Aridis Pharmaceuticals LLC, H1 2015 26

Acinetobacter Infections-Pipeline by AstraZeneca PLC, H1 2015 27

Acinetobacter Infections-Pipeline by AvidBiotics Corp., H1 2015 28

Acinetobacter Infections-Pipeline by ConjuGon, Inc., H1 2015 29

Acinetobacter Infections-Pipeline by Emergent BioSolutions Inc., H1 2015 30

Acinetobacter Infections-Pipeline by FAB Pharma, H1 2015 31

Acinetobacter Infections-Pipeline by LegoChem Biosciences, Inc, H1 2015 32

Acinetobacter Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 33

Acinetobacter Infections-Pipeline by Microbiotix, Inc., H1 2015 34

Acinetobacter Infections-Pipeline by Northern Antibiotics Oy, H1 2015 35

Acinetobacter Infections-Pipeline by Nosopharm SAS, H1 2015 36

Acinetobacter Infections-Pipeline by Novan, Inc., H1 2015 37

Acinetobacter Infections-Pipeline by Omnia Molecular Ltd., H1 2015 38

Acinetobacter Infections-Pipeline by Pfizer Inc., H1 2015 39

Acinetobacter Infections-Pipeline by Phylogica Limited, H1 2015 40

Acinetobacter Infections-Pipeline by Sarepta Therapeutics, Inc., H1 2015 41

Acinetobacter Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 42

Acinetobacter Infections-Pipeline by Shionogi & Co., Ltd., H1 2015 43

Acinetobacter Infections-Pipeline by Synthetic Biologics, Inc., H1 2015 44

Acinetobacter Infections-Pipeline by Techulon, Inc., H1 2015 45

Acinetobacter Infections-Pipeline by Trana Discovery, Inc., H1 2015 46

Acinetobacter Infections-Pipeline by Vaxdyn, S.L., H1 2015 47

Assessment by Monotherapy Products, H1 2015 48

Assessment by Combination Products, H1 2015 49

Number of Products by Stage and Target, H1 2015 51

Number of Products by Stage and Mechanism of Action, H1 2015 53

Number of Products by Stage and Route of Administration, H1 2015 55

Number of Products by Stage and Molecule Type, H1 2015 57

Acinetobacter Infections Therapeutics-Recent Pipeline Updates, H1 2015 108

Acinetobacter Infections-Dormant Projects, H1 2015 112

List of Figures

Number of Products under Development for Acinetobacter Infections, H1 2015 12

Number of Products under Development for Acinetobacter Infections-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 48

Number of Products by Top 10 Targets, H1 2015 50

Number of Products by Stage and Top 10 Targets, H1 2015 51

Number of Products by Top 10 Mechanism of Actions, H1 2015 52

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 53

Number of Products by Top 10 Routes of Administration, H1 2015 54

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 55

Number of Products by Top 10 Molecule Types, H1 2015 56

Number of Products by Stage and Top 10 Molecule Types, H1 2015 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Achaogen Inc.

Adenium Biotech ApS

AmpliPhi Biosciences Corporation

Aridis Pharmaceuticals LLC

AstraZeneca PLC

AvidBiotics Corp.

ConjuGon, Inc.

Emergent BioSolutions Inc.

FAB Pharma

LegoChem Biosciences, Inc

Melinta Therapeutics, Inc

Microbiotix, Inc.

Northern Antibiotics Oy

Nosopharm SAS

Novan, Inc.

Omnia Molecular Ltd.

Pfizer Inc.

Phylogica Limited

Sarepta Therapeutics, Inc.


Shionogi & Co., Ltd.

Synthetic Biologics, Inc.

Techulon, Inc.

Trana Discovery, Inc.

Vaxdyn, S.L.

Acinetobacter Infections Therapeutic Products under Development, Key Players in Acinetobacter Infections Therapeutics, Acinetobacter Infections Pipeline Overview, Acinetobacter Infections Pipeline, Acinetobacter Infections Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]